We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status More information
         
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Investor webcast
Clazosentan Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Phase 3 Investor webcast
Daridorexant Dual orexin receptor antagonist Insomnia Phase 3 Investor webcast
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3 Investor webcast
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2  
Selatogrel P2Y12 receptor antagonist Suspected acute myocardial infarction Phase 2  
ACT-774312 CRTH2 receptor antagonist Nasal polyposis Phase 2  
ACT-519276 GBA2/GCS inhibitor Rare CNS diseases Phase 1  
ACT-539313 Selective orexin 1 receptor antagonist Psychiatric disorders Phase 1  
ACT-709478** T-type calcium channel blocker Epilepsy Phase 1  
ACT-1004-1239 - Immunology / Cancer Immunotherapy Phase 1  
ACT-1014-6470 - Immunology Initiating
Phase 1		  


* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide
** Idorsia has granted to a third party an option to license ACT-709478, this option will expire 60 days after the IND submission to the FDA, which is planned for late 2019

Idorsia has the option to license vamorolone from ReveraGen Inc. and has granted to Santhera Holding Ltd. the option to sub-license vamorolone worldwide (except Japan and South-Korea) for all indications.

"The team I work with encourages me to be self-critical with results obtained and act on my own initiative."

Senior Lab Technician, Pharmacology & Preclinical Development